Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Survodutide passes its cardiovascular safety test. The novel glucagon/GLP-1 dual agonist was noninferior to placebo for major adverse cardiovascular events in the SYNCHRONIZE-CVOT trial, involving over 5,500 high-risk patients with obesity. It also delivered meaningful cardiometabolic benefits — lower blood pressure, reduced waist circumference, and significant weight loss — without raising CV risk.
Survodutide, Boehringer Ingelheim's investigational glucagon/GLP-1 dual agonist, has cleared a critical cardiovascular safety hurdle. Results from the SYNCHRONIZE-CVOT trial — presented at the American Heart Association Scientific Sessions and published in The Lancet — showed the drug was noninferior to placebo for a 5-point major adverse cardiovascular events (MACE) composite endpoint in a high-risk population with obesity.
The trial enrolled 5,508 patients with a mean age of 60.8 years, most of whom had hypertension (88%), dyslipidemia (83%), and over half had coronary artery disease or type 2 diabetes. Beyond safety, survodutide also delivered meaningful metabolic benefits at 72 weeks, including significant reductions in systolic blood pressure, waist circumference, and body weight compared to placebo.
By the Numbers
Why it matters: While survodutide proved it won't cause cardiovascular harm, it hasn't yet demonstrated CV superiority — a bar already cleared by some GLP-1 agents. Clinicians will need to weigh this safety profile against agents with proven CV outcome benefits when choosing therapies for high-risk patients.
